1
|
Klussmann JP, Grosheva M, Meiser P, Lehmann C, Nagy E, Szijártó V, Nagy G, Konrat R, Flegel M, Holzer F, Groß D, Steinmetz C, Scherer B, Gruell H, Schlotz M, Klein F, de Aragão PA, Morr H, Al Saleh H, Bilstein A, Russo B, Müller-Scholtz S, Acikel C, Sahin H, Werkhäuser N, Allekotte S, Mösges R. Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients. Sci Rep 2023; 13:6839. [PMID: 37100830 PMCID: PMC10132439 DOI: 10.1038/s41598-023-32546-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Accepted: 03/29/2023] [Indexed: 04/28/2023] Open
Abstract
With the changing epidemiology of COVID-19 and its impact on our daily lives, there is still an unmet need of COVID-19 therapies treating early infections to prevent progression. The current study was a randomized, parallel, double-blind, placebo-controlled trial. Ninety SARS-CoV-2 positive patients were randomized into 3 groups receiving placebo, 0.02% or 0.1% azelastine nasal spray for 11 days, during which viral loads were assessed by quantitative PCR. Investigators assessed patients' status throughout the trial including safety follow-ups (days 16 and 60). Symptoms were documented in patient diaries. Initial viral loads were log10 6.85 ± 1.31 (mean ± SD) copies/mL (ORF 1a/b gene). After treatment, virus load was reduced in all groups (p < 0.0001) but was greater in the 0.1% group compared to placebo (p = 0.007). In a subset of patients (initial Ct < 25) viral load was strongly reduced on day 4 in the 0.1% group compared to placebo (p = 0.005). Negative PCR results appeared earlier and more frequently in the azelastine treated groups: being 18.52% and 21.43% in the 0.1% and 0.02% groups, respectively, compared to 0% for placebo on day 8. Comparable numbers of adverse events occurred in all treatment groups with no safety concerns. The shown effects of azelastine nasal spray may thus be suggestive of azelastine's potential as an antiviral treatment.Trial registration: The study was registered in the German Clinical Trial Register (DRKS-ID: DRKS00024520; Date of Registration in DRKS: 12/02/2021). EudraCT number: 2020-005544-34.
Collapse
Affiliation(s)
- Jens Peter Klussmann
- Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany
- Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany
| | - Maria Grosheva
- Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany
| | - Peter Meiser
- URSAPHARM Arzneimittel GmbH, Industriestraße 35, 66129, Saarbruecken, Germany
| | - Clara Lehmann
- Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany
- Department I of Internal Medicine, Division of Infectious Diseases, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany
- German Center for Infection Research (DZIF) Location Bonn-Cologne, Kerpener Str. 62, 50937, Cologne, Germany
| | - Eszter Nagy
- CEBINA GmbH, Karl-Farkas-Gasse 22, 1030, Vienna, Austria
| | | | - Gábor Nagy
- CEBINA GmbH, Karl-Farkas-Gasse 22, 1030, Vienna, Austria
| | - Robert Konrat
- Department of Structural and Computational Biology, Max F. Perutz Laboratories, University of Vienna, Dr.-Bohr-Gasse 9, 1030, Vienna, Austria
| | - Michael Flegel
- URSAPHARM Arzneimittel GmbH, Industriestraße 35, 66129, Saarbruecken, Germany
| | - Frank Holzer
- URSAPHARM Arzneimittel GmbH, Industriestraße 35, 66129, Saarbruecken, Germany
| | - Dorothea Groß
- URSAPHARM Arzneimittel GmbH, Industriestraße 35, 66129, Saarbruecken, Germany
| | - Charlotte Steinmetz
- URSAPHARM Arzneimittel GmbH, Industriestraße 35, 66129, Saarbruecken, Germany
| | - Barbara Scherer
- URSAPHARM Arzneimittel GmbH, Industriestraße 35, 66129, Saarbruecken, Germany
| | - Henning Gruell
- Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany
| | - Maike Schlotz
- Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany
| | - Florian Klein
- German Center for Infection Research (DZIF) Location Bonn-Cologne, Kerpener Str. 62, 50937, Cologne, Germany
- Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany
| | - Paula Aguiar de Aragão
- Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany
| | - Henning Morr
- Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany
| | - Helal Al Saleh
- Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany
| | | | - Belisa Russo
- ClinCompetence Cologne GmbH, Theodor-Heuss-Ring 14, 50668, Cologne, Germany
| | | | - Cengizhan Acikel
- ClinCompetence Cologne GmbH, Theodor-Heuss-Ring 14, 50668, Cologne, Germany
| | - Hacer Sahin
- ClinCompetence Cologne GmbH, Theodor-Heuss-Ring 14, 50668, Cologne, Germany
| | - Nina Werkhäuser
- ClinCompetence Cologne GmbH, Theodor-Heuss-Ring 14, 50668, Cologne, Germany
| | - Silke Allekotte
- ClinCompetence Cologne GmbH, Theodor-Heuss-Ring 14, 50668, Cologne, Germany
| | - Ralph Mösges
- ClinCompetence Cologne GmbH, Theodor-Heuss-Ring 14, 50668, Cologne, Germany.
- Institute of Medical Statistics and Computational Biology (IMSB), Faculty of Medicine, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
| |
Collapse
|
2
|
Meiers J, Dastbaz J, Adam S, Rasheed S, Kirsch SH, Meiser P, Gross P, Müller R, Titz A. Pineapple Lectin AcmJRL Binds SARS-CoV-2 Spike Protein in a Carbohydrate-Dependent Fashion. Chembiochem 2023; 24:e202200463. [PMID: 36420784 PMCID: PMC10107836 DOI: 10.1002/cbic.202200463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Revised: 11/23/2022] [Accepted: 11/24/2022] [Indexed: 11/27/2022]
Abstract
The highly glycosylated spike protein of SARS-CoV-2 is essential for infection and constitutes a prime target for antiviral agents and vaccines. The pineapple-derived jacalin-related lectin AcmJRL is present in the medication bromelain in significant quantities and has previously been described to bind mannosides. Here, we performed a large ligand screening of AcmJRL by glycan array analysis, quantified the interaction with carbohydrates and validated high-mannose glycans as preferred ligands. Because the SARS-CoV-2 spike protein was previously reported to carry a high proportion of high-mannose N-glycans, we tested the binding of AcmJRL to the recombinantly produced extraviral domain of spike protein. We could demonstrate that AcmJRL binds the spike protein with a low-micromolar KD in a carbohydrate-dependent fashion.
Collapse
Affiliation(s)
- Joscha Meiers
- Chemical Biology of Carbohydrates (CBCH)Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)Helmholtz Centre for Infection Research66123SaarbrückenGermany
- Deutsches Zentrum für Infektionsforschung (DZIF)Standort Hannover-Braunschweig38124BraunschweigGermany
- Department of ChemistrySaarland University66123SaarbrückenGermany
| | - Jan Dastbaz
- Deutsches Zentrum für Infektionsforschung (DZIF)Standort Hannover-Braunschweig38124BraunschweigGermany
- Department of PharmacySaarland University66123SaarbrückenGermany
- Microbial Natural Products (MINS)Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)Helmholtz Centre for Infection Research66123SaarbrückenGermany
| | - Sebastian Adam
- Deutsches Zentrum für Infektionsforschung (DZIF)Standort Hannover-Braunschweig38124BraunschweigGermany
- Drug Design and Optimisation (DDOP)Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)Helmholtz Centre for Infection Research66123SaarbrückenGermany
| | - Sari Rasheed
- Deutsches Zentrum für Infektionsforschung (DZIF)Standort Hannover-Braunschweig38124BraunschweigGermany
- Department of PharmacySaarland University66123SaarbrückenGermany
- Microbial Natural Products (MINS)Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)Helmholtz Centre for Infection Research66123SaarbrückenGermany
| | - Susanne H. Kirsch
- Deutsches Zentrum für Infektionsforschung (DZIF)Standort Hannover-Braunschweig38124BraunschweigGermany
- Microbial Natural Products (MINS)Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)Helmholtz Centre for Infection Research66123SaarbrückenGermany
| | - Peter Meiser
- URSAPHARM Arzneimittel GmbH66129SaarbrückenGermany
| | - Peter Gross
- Hochschule KaiserslauternProtein Chemistry Group66953PirmasensGermany
| | - Rolf Müller
- Deutsches Zentrum für Infektionsforschung (DZIF)Standort Hannover-Braunschweig38124BraunschweigGermany
- Department of PharmacySaarland University66123SaarbrückenGermany
- Microbial Natural Products (MINS)Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)Helmholtz Centre for Infection Research66123SaarbrückenGermany
| | - Alexander Titz
- Chemical Biology of Carbohydrates (CBCH)Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)Helmholtz Centre for Infection Research66123SaarbrückenGermany
- Deutsches Zentrum für Infektionsforschung (DZIF)Standort Hannover-Braunschweig38124BraunschweigGermany
- Department of ChemistrySaarland University66123SaarbrückenGermany
| |
Collapse
|
3
|
Masood MI, Schäfer KH, Naseem M, Weyland M, Meiser P. Troxerutin flavonoid has neuroprotective properties and increases neurite outgrowth and migration of neural stem cells from the subventricular zone. PLoS One 2020; 15:e0237025. [PMID: 32797057 PMCID: PMC7428079 DOI: 10.1371/journal.pone.0237025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2020] [Accepted: 07/17/2020] [Indexed: 02/07/2023] Open
Abstract
Troxerutin (TRX) is a water-soluble flavonoid which occurs commonly in the edible plants. Recent studies state that TRX improves the functionality of the nervous system and neutralizes Amyloid-ß induced neuronal toxicity. In this study, an in vitro assay based upon Neural stem cell (NSCs) isolated from the subventricular zone of the postnatal balb/c mice was established to explore the impact of TRX on individual neurogenesis processes in general and neuroprotective effect against ß-amyloid 1-42 (Aß42) induced inhibition in differentiation in particular. NSCs were identified exploiting immunostaining of the NSCs markers. Neurosphere clonogenic assay and BrdU/Ki67 immunostaining were employed to unravel the impact of TRX on proliferation. Differentiation experiments were carried out for a time span lasting from 48 h to 7 days utilizing ß-tubulin III and GFAP as neuronal and astrocyte marker respectively. Protective effects of TRX on Aß42 induced depression of NSCs differentiation were determined after 48 h of application. A neurosphere migration assay was carried out for 24 h in the presence and absence of TRX. Interestingly, TRX enhanced neuronal differentiation of NSCs in a dose-dependent manner after 48 h and 7 days of incubation and significantly enhanced neurite growth. A higher concentration of TRX also neutralized the inhibitory effects of Aß42 on neurite outgrowth and length after 48 h of incubation. TRX significantly stimulated cell migration. Overall, TRX not only promoted NSCs differentiation and migration but also neutralized the inhibitory effects of Aß42 on NSCs. TRX, therefore, offers an interesting lead structure from the perspective of drug design especially to promote neurogenesis in neurological disorders i.e. Alzheimer's disease.
Collapse
Affiliation(s)
- Muhammad Irfan Masood
- Division of Bioorganic Chemistry, School of Pharmacy, Saarland University, Saarbrücken, Germany
- ENS Group, University of Applied Sciences Kaiserslautern, Zweibrücken, Germany
- Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan
| | | | - Mahrukh Naseem
- Department of Zoology, University of Balochistan, Quetta, Pakistan
| | - Maximilian Weyland
- ENS Group, University of Applied Sciences Kaiserslautern, Zweibrücken, Germany
| | - Peter Meiser
- Medical Scientific Department GM, URSAPHARM Arzneimittel GmbH, Saarbrücken, Germany
| |
Collapse
|
4
|
Gross P, Seelert H, Meiser P, Müller R. Characterization of bromelain indicates a molar excess of inhibitor vs. enzyme molecules, a Jacalin-like lectin and Maillard reaction products. J Pharm Biomed Anal 2020; 181:113075. [DOI: 10.1016/j.jpba.2019.113075] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2019] [Revised: 12/11/2019] [Accepted: 12/21/2019] [Indexed: 10/25/2022]
|
5
|
Bakuradze T, Becker D, Reischmann J, Meiser P, Galan J, Richling E. Protection from DNA Damage by Use of an Aronia Food Supplement—Results from a Pilot Human Intervention Study. ACTA ACUST UNITED AC 2019. [DOI: 10.1007/s40495-019-00178-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
6
|
Zwergel C, Czepukojc B, Evain-Bana E, Xu Z, Stazi G, Mori M, Patsilinakos A, Mai A, Botta B, Ragno R, Bagrel D, Kirsch G, Meiser P, Jacob C, Montenarh M, Valente S. Novel coumarin- and quinolinone-based polycycles as cell division cycle 25-A and -C phosphatases inhibitors induce proliferation arrest and apoptosis in cancer cells. Eur J Med Chem 2017; 134:316-333. [DOI: 10.1016/j.ejmech.2017.04.012] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Revised: 04/03/2017] [Accepted: 04/06/2017] [Indexed: 01/06/2023]
|
7
|
Luniak N, Meiser P, Burkart S, Müller R. Heterologous expression of the plant cysteine protease bromelain and its inhibitor in Pichia pastoris. Biotechnol Prog 2016; 33:54-65. [PMID: 27860461 DOI: 10.1002/btpr.2405] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Revised: 11/08/2016] [Indexed: 12/11/2022]
Abstract
Expression of proteases in heterologous hosts remains an ambitious challenge due to severe problems associated with digestion of host proteins. On the other hand, proteases are broadly used in industrial applications and resemble promising drug candidates. Bromelain is an herbal drug that is medicinally used for treatment of oedematous swellings and inflammatory conditions and consists in large part of proteolytic enzymes. Even though various experiments underline the requirement of active cysteine proteases for biological activity, so far no investigation succeeded to clearly clarify the pharmacological mode of action of bromelain. The potential role of proteases themselves and other molecules of this multi-component extract currently remain largely unknown or ill defined. Here, we set out to express several bromelain cysteine proteases as well as a bromelain inhibitor molecule in order to gain defined molecular entities for subsequent studies. After cloning the genes from its natural source Ananas comosus (pineapple plant) into Pichia pastoris and subsequent fermentation and purification, we obtained active protease and inhibitor molecules which were subsequently biochemically characterized. Employing purified bromelain fractions paves the way for further elucidation of pharmacological activities of this natural product. © 2016 American Institute of Chemical Engineers Biotechnol. Prog., 33:54-65, 2017.
Collapse
Affiliation(s)
- Nora Luniak
- Ursapharm Arzneimittel GmbH, Industriestraße 35, Saarbrücken, 66129, Germany
| | - Peter Meiser
- Ursapharm Arzneimittel GmbH, Industriestraße 35, Saarbrücken, 66129, Germany
| | - Sonja Burkart
- PharmBioTec GmbH, Science Park 1, Saarbrücken, 66123, Germany
| | - Rolf Müller
- Helmholtz Institute for Pharmaceutical Research Saarland, Department of Microbial Natural Products, Helmholtz Centre for Infection Research and Pharmaceutical Biotechnology at Saarland University, Saarbrücken, 66041, Germany
| |
Collapse
|
8
|
Bormann KH, Weber K, Kloppenburg H, Koch A, Meiser P, Gellrich NC. Perioperative Bromelain Therapy after Wisdom Teeth Extraction - A Randomized, Placebo-Controlled, Double-Blinded, Three-Armed, Cross-Over Dose-Finding Study. Phytother Res 2016; 30:2012-2019. [DOI: 10.1002/ptr.5707] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2016] [Revised: 07/18/2016] [Accepted: 08/07/2016] [Indexed: 11/10/2022]
Affiliation(s)
- Kai-Hendrik Bormann
- Department of Oral and Maxillofacial Surgery; Hannover Medical School; Carl-Neuberg-Strasse 1 30625 Hannover Germany
| | - Kristina Weber
- Institute for Biostatistics; Hannover Medical School; Carl-Neuberg-Strasse 1 30625 Hannover Germany
| | - Heike Kloppenburg
- Department of Oral and Maxillofacial Surgery; Hannover Medical School; Carl-Neuberg-Strasse 1 30625 Hannover Germany
| | - Armin Koch
- Institute for Biostatistics; Hannover Medical School; Carl-Neuberg-Strasse 1 30625 Hannover Germany
| | - Peter Meiser
- Ursapharm Arzneimittel GmbH; Industriestraße 35 66129 Saarbrücken Germany
| | - Nils-Claudius Gellrich
- Department of Oral and Maxillofacial Surgery; Hannover Medical School; Carl-Neuberg-Strasse 1 30625 Hannover Germany
| |
Collapse
|
9
|
Valente S, Xu Z, Bana E, Zwergel C, Mai A, Jacob C, Meiser P, Bagrel D, Silva AMS, Kirsch G. Reactivity of 4-Vinyl-2H-1-benzopyran-2-ones in Diels-Alder Cycloaddition Reactions: Access to Coumarin-Based Polycycles with Cdc25 Phosphatase-Inhibiting Activity. European J Org Chem 2013. [DOI: 10.1002/ejoc.201201736] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
10
|
Müller S, März R, Schmolz M, Drewelow B, Eschmann K, Meiser P. Placebo-controlled Randomized Clinical Trial on the Immunomodulating Activities of Low- and High-Dose Bromelain after Oral Administration - New Evidence on the Antiinflammatory Mode of Action of Bromelain. Phytother Res 2012; 27:199-204. [DOI: 10.1002/ptr.4678] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2011] [Revised: 02/13/2012] [Accepted: 02/20/2012] [Indexed: 11/10/2022]
Affiliation(s)
- Silke Müller
- Institute for Clinical Pharmacology, Medical Faculty; University of Rostock; Schillingallee 70; 18057; Rostock; Germany
| | - Reinhard März
- SCIRM; Ohm-University of Applied Sciences Nuremberg; Peter-Hannweg-Str. 8; 90768; Fürth; Germany
| | - Manfred Schmolz
- EDI (Experimental and Diagnostic Immunology) GmbH; Aspenhaustr. 25; 72770; Reutlingen; Germany
| | - Bernd Drewelow
- Institute for Clinical Pharmacology, Medical Faculty; University of Rostock; Schillingallee 70; 18057; Rostock; Germany
| | - Klaus Eschmann
- Ursapharm Arzneimittel GmbH; Industriestraße 35; 66129; Saarbrücken; Germany
| | - Peter Meiser
- Ursapharm Arzneimittel GmbH; Industriestraße 35; 66129; Saarbrücken; Germany
| |
Collapse
|
11
|
Xu Z, Du P, Meiser P, Jacob C. Proanthocyanidins: oligomeric structures with unique biochemical properties and great therapeutic promise. Nat Prod Commun 2012; 7:381-388. [PMID: 22545414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023] Open
Abstract
Proanthocyanidins represent a unique class of oligomeric and polymeric secondary metabolites found ubiquitously and in considerable amounts in plants and some algae. These substances exhibit a range of rather surprising physical and chemical properties which, once applied to living organisms, are translated into a multitude of biological activities. The latter include antioxidant properties, cancer chemoprevention, anti-inflammatory and anti-diabetic effects as well as some exceptional, yet highly interesting activities, such as anti-nutritional and antimicrobial activity. Despite the wide range of activities and possible medical/agricultural applications of proanthocyanidins, many questions still remain, including issues related to bioavailability, metabolism and the precise biochemical, extra- and intracellular targets and mode(s) of action of these highly potent materials. Among the various physical and chemical interactions of such substances, strong binding to proteins appears to form the basis of many of their biological activities. Once easy-to-use synthetic methods to produce appropriate quantities of pure proanthocyanidins are available, it will be possible to identify the prime biological targets of these oligomers, study oligomer-protein interactions in more detail and develop possible practical applications in medicine and agriculture.
Collapse
Affiliation(s)
- Zhanjie Xu
- Division of Bioorganic Chemistry, School of Pharmacy, Saarland University, Campus B 2.1., D-66123 Saarbruecken, Germany
| | | | | | | |
Collapse
|
12
|
Abstract
Proanthocyanidins represent a unique class of oligomeric and polymeric secondary metabolites found ubiquitously and in considerable amounts in plants and some algae. These substances exhibit a range of rather surprising physical and chemical properties which, once applied to living organisms, are translated into a multitude of biological activities. The latter include antioxidant properties, cancer chemoprevention, anti-inflammatory and anti-diabetic effects as well as some exceptional, yet highly interesting activities, such as anti-nutritional and antimicrobial activity. Despite the wide range of activities and possible medical/agricultural applications of proanthocyanidins, many questions still remain, including issues related to bioavailability, metabolism and the precise biochemical, extra- and intracellular targets and mode(s) of action of these highly potent materials. Among the various physical and chemical interactions of such substances, strong binding to proteins appears to form the basis of many of their biological activities. Once easy-to-use synthetic methods to produce appropriate quantities of pure proanthocyanidins are available, it will be possible to identify the prime biological targets of these oligomers, study oligomer-protein interactions in more detail and develop possible practical applications in medicine and agriculture.
Collapse
Affiliation(s)
- Zhanjie Xu
- Division of Bioorganic Chemistry, School of Pharmacy, Saarland University, Campus B 2.1., D-66123 Saarbruecken, Germany
- Ursapharm Arzneimittel GmbH, D-66129 Saarbrücken, Germany
| | - Peng Du
- Division of Bioorganic Chemistry, School of Pharmacy, Saarland University, Campus B 2.1., D-66123 Saarbruecken, Germany
| | - Peter Meiser
- Ursapharm Arzneimittel GmbH, D-66129 Saarbrücken, Germany
| | - Claus Jacob
- Division of Bioorganic Chemistry, School of Pharmacy, Saarland University, Campus B 2.1., D-66123 Saarbruecken, Germany
| |
Collapse
|
13
|
Johann K, Eschmann K, Meiser P. Keine klinische Evidenz für ein erhöhtes Blutungsrisiko durch Bromelain bei perioperativem Einsatz. Sportverletz Sportschaden 2011; 25:108-13. [DOI: 10.1055/s-0031-1273307] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
14
|
Kopp M, Irschik H, Gemperlein K, Buntin K, Meiser P, Weissman KJ, Bode HB, Müller R. Insights into the complex biosynthesis of the leupyrrins in Sorangium cellulosum So ce690. Mol Biosyst 2011; 7:1549-63. [PMID: 21365089 DOI: 10.1039/c0mb00240b] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
The anti-fungal leupyrrins are secondary metabolites produced by several strains of the myxobacterium Sorangium cellulosum. These intriguing compounds incorporate an atypically substituted γ-butyrolactone ring, as well as pyrrole and oxazolinone functionalities, which are located within an unusual asymmetrical macrodiolide. Previous feeding studies revealed that this novel structure arises from the homologation of four distinct structural units, nonribosomally-derived peptide, polyketide, isoprenoid and a dicarboxylic acid, coupled with modification of the various building blocks. Here we have attempted to reconcile the biosynthetic pathway proposed on the basis of the feeding studies with the underlying enzymatic machinery in the S. cellulosum strain So ce690. Gene products can be assigned to many of the suggested steps, but inspection of the gene set provokes the reconsideration of several key transformations. We support our analysis by the reconstitution in vitro of the biosynthesis of the pyrrole carboxylic starter unit along with gene inactivation. In addition, this study reveals that a significant proportion of the genes for leupyrrin biosynthesis are located outside the core cluster, a 'split' organization which is increasingly characteristic of the myxobacteria. Finally, we report the generation of four novel deshydroxy leupyrrin analogues by genetic engineering of the pathway.
Collapse
Affiliation(s)
- Maren Kopp
- Helmholtz Institute for Pharmaceutical Research, Helmholtz Center for Infection Research and Department of Pharmaceutical Biotechnology, Saarland University, PO Box 151150, 66041 Saarbrücken, Germany
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Mösges R, Kaatz V, Schmalz P, Meiser P, Eschmann K. Glycerol lidocaine eardrops for the treatment of acute abacterial otitis externa. ACTA ACUST UNITED AC 2010; 60:427-31. [PMID: 20712132 DOI: 10.1055/s-0031-1296307] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
Abstract
Inflammations of the external auditory canal number among the most frequently occurring ear-nose-throat diseases. For local treatment, substances from various groups of active ingredients are used as combinations and as single-agent drugs, e.g. antibiotics, glucocorticoids or analgesics [1]. In the case of acute otitis externa, treatment measures focus on the reduction of pain and swelling. The study described here investigates the efficacy and safety of glycerol lidocaine eardrops for the treatment of acute abacterial otitis externa (CAS No. for glycerol: 56-81-5, lidocaine-HCl: 73-78-9). In this double-blind, three-arm study, 105 patients diagnosed with acute abacterial otitis externa were included and randomized to receive either glycerol eardrops, glycerol eardrops with 0.5% lidocaine, or glycerol eardrops with 2% lidocaine for seven days. The primary outcome parameter was the change of the five typical clinical symptoms, earache, itching, otorrhea, hearing impairment, and "clogged ear" at Visit 2 (Day 7) based on the initial examination on Day 0. Both therapy groups treated with a combination of glycerol and lidocaine exhibited definite improvement in overall symptoms after seven days. This improvement differed from the mild reduction of symptoms under treatment with glycerol eardrops alone. Overall improvement of symptoms, expressed by the area under the curve of the baseline-adjusted symptom sum score, yielded a mean value of 10.95 (standard deviation 27.4) for the morning survey of the groups receiving eardrops containing only glycerol; in comparison, for eardrops containing glycerol and 2% lidocaine it was 15.71 (+/- 23.6) and for glycerol with 0.5% lidocaine, 23.16 (+/- 19.4). No severe adverse events occurred. Five adverse events were documented during the clinical investigation, none of which was considered by the investigators to be related to the study medication. Local therapy with glycerol lidocaine eardrops is a safe, and cost-effective treatment for the widely spread clinical picture of acute abacterial otitis externa. The advantage regarding efficacy of this combination compared with glycerol eardrops must be demonstrated in an adequately powered clinical trial.
Collapse
Affiliation(s)
- Ralph Mösges
- Institute of Medical Statistics, Informatics and Epidemiology (IMSIE), University Hospital of Cologne, Germany.
| | | | | | | | | |
Collapse
|
16
|
Meiser P, Müller R. Two Functionally Redundant Sfp‐Type 4′‐Phosphopantetheinyl Transferases Differentially Activate Biosynthetic Pathways inMyxococcus xanthus. Chembiochem 2008; 9:1549-53. [DOI: 10.1002/cbic.200800077] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
17
|
Bode HB, Meiser P, Klefisch T, Cortina NSDJ, Krug D, Göhring A, Schwär G, Mahmud T, Elnakady YA, Müller R. Mutasynthesis-derived myxalamids and origin of the isobutyryl-CoA starter unit of myxalamid B. Chembiochem 2008; 8:2139-44. [PMID: 17955482 DOI: 10.1002/cbic.200700401] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Myxalamids are potent inhibitors of the eukaryotic electron transport chain produced by different myxobacteria. Here, we describe the identification of the myxalamid biosynthesis gene cluster from Myxococcus xanthus. Additionally, new myxalamids (5-13) have been obtained by mutasynthesis from bkd mutants of M. xanthus and Stigmatella aurantiaca. Moreover, as these bkd mutants are still able to produce myxalamid B (2), the origin of the isobutyryl-CoA (IB-CoA) starter unit required for its biosynthesis has been determined. In a M. xanthus bkd mutant, IB-CoA originates from valine, but in S. aurantiaca this starter unit is derived from alpha-oxidation of iso-odd fatty acids, thereby connecting primary and secondary metabolism.
Collapse
Affiliation(s)
- Helge B Bode
- Institut für Pharmazeutische Biotechnologie, Universität des Saarlandes, Postfach 151150, 66041 Saarbrücken, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Wenzel SC, Meiser P, Binz TM, Mahmud T, Müller R. Nonribosomal peptide biosynthesis: point mutations and module skipping lead to chemical diversity. Angew Chem Int Ed Engl 2007; 45:2296-301. [PMID: 16506259 DOI: 10.1002/anie.200503737] [Citation(s) in RCA: 87] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Silke C Wenzel
- Pharmaceutical Biotechnology, Saarland University, P.O. Box 151150, 66041 Saarbrücken, Germany
| | | | | | | | | |
Collapse
|
19
|
Meiser P, Bode HB, Müller R. The unique DKxanthene secondary metabolite family from the myxobacterium Myxococcus xanthus is required for developmental sporulation. Proc Natl Acad Sci U S A 2006; 103:19128-33. [PMID: 17148609 PMCID: PMC1748187 DOI: 10.1073/pnas.0606039103] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Under starvation conditions myxobacteria form multicellular fruiting bodies in which vegetative cells differentiate into heat- and desiccation-resistant myxospores. Myxobacteria in general are a rich source of secondary metabolites that often exhibit biological activities rarely found in nature. Although the involvement of a yellow compound in sporulation and fruiting body formation of Myxococcus xanthus was described almost 30 years ago, the chemical principle of the pigment remained elusive. This work presents the isolation and structure elucidation of a unique class of pigments that were named DKxanthenes (DKX). The corresponding biosynthetic gene cluster was identified, and DKX-negative mutants were constructed to investigate the physiological role of DKX during development. In these mutants, fruiting body formation was delayed. Moreover, severely reduced amounts of viable spores were observed after 120 h of starvation, whereas no viable spores were formed at all after 72 h. The addition of purified DKX to the mutants resulted in the formation of viable spores after 72 h. Even though an antioxidative activity could be assigned to DKX, the true biochemical mechanism underlying the complementation remains to be elucidated.
Collapse
Affiliation(s)
- Peter Meiser
- Pharmaceutical Biotechnology, Saarland University, P.O. Box 151150, 66041 Saarbrücken, Germany
| | - Helge B. Bode
- Pharmaceutical Biotechnology, Saarland University, P.O. Box 151150, 66041 Saarbrücken, Germany
| | - Rolf Müller
- Pharmaceutical Biotechnology, Saarland University, P.O. Box 151150, 66041 Saarbrücken, Germany
- *To whom correspondence should be addressed. E-mail:
| |
Collapse
|
20
|
Simunovic V, Zapp J, Rachid S, Krug D, Meiser P, Müller R. Myxovirescin A Biosynthesis is Directed by Hybrid Polyketide Synthases/Nonribosomal Peptide Synthetase, 3-Hydroxy-3-Methylglutaryl-CoA Synthases, and trans-Acting Acyltransferases. Chembiochem 2006; 7:1206-20. [PMID: 16835859 DOI: 10.1002/cbic.200600075] [Citation(s) in RCA: 118] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Myxococcus xanthus DK1622 is shown to be a producer of myxovirescin (antibiotic TA) antibiotics. The myxovirescin biosynthetic gene cluster spans at least 21 open reading frames (ORFs) and covers a chromosomal region of approximately 83 kb. In silico analysis of myxovirescin ORFs in conjunction with genetic studies suggests the involvement of four type I polyketide synthases (PKSs; TaI, TaL, TaO, and TaP), one major hybrid PKS/NRPS (Ta-1), and a number of monofunctional enzymes similar to the ones involved in type II fatty-acid biosynthesis (FAB). Whereas deletion of either taI or taL causes a dramatic drop in myxovirescin production, deletion of both genes (DeltataIL) leads to the complete loss of myxovirescin production. These results suggest that both TaI and TaL PKSs might act in conjunction with a methyltransferase, reductases, and a monooxygenase to produce the 2-hydroxyvaleryl-S-ACP starter that is proposed to act as the biosynthetic primer in the initial condensation reaction with glycine. Polymerization of the remaining 11 acetates required for lactone formation is directed by 12 modules of Ta-1, TaO, and TaP megasynthetases. All modules, except for the first module of TaL, lack cognate acyltransferase (AT) domains. Furthermore, deletion of a discrete tandem AT-encoded by taV-blocks myxovirescin production; this suggests an "in trans" mode of action. To embellish the macrocycle with methyl and ethyl moieties, assembly of the myxovirescin scaffold is proposed to switch twice from PKS to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA)-like biochemistry during biosynthesis. Disruption of the S-adenosylmethionine (SAM)-dependent methyltransferase, TaQ, shifts production toward two novel myxovirescin analogues, designated myxovirescin Q(a) and myxovirescin Q(c). NMR analysis of purified myxovirescin Q(a) revealed the loss of the methoxy carbon atom. This novel analogue lacks bioactivity against E. coli.
Collapse
Affiliation(s)
- Vesna Simunovic
- Pharmaceutical Biotechnology, Saarland University, Im Stadtwald, 66123 Saarbrücken, Germany
| | | | | | | | | | | |
Collapse
|
21
|
Wenzel SC, Meiser P, Binz TM, Mahmud T, Müller R. Nichtribosomale Peptidbiosynthese: Punktmutationen und Überspringen eines Moduls führen zu chemischer Diversität. Angew Chem Int Ed Engl 2006. [DOI: 10.1002/ange.200503737] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
22
|
Korabiowska M, Meiser P, Honig J, Kellner S, Brinck U, Fischer G. Analysis of ploidy status in progression of head and neck cancers by DNA image cytometry. Oncol Rep 1996; 3:1165-8. [PMID: 21594531 DOI: 10.3892/or.3.6.1165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Eight cases of leukoplakia, 25 lingual cancers, 15 cancers of the floor of the oral cavity, 11 pharyngeal cancers and 14 lymph nodes with squamous cell cancer metastases were stained using the Feulgen method to evaluate the ploidy status and ploidy related parameters. All leukoplakias were euploid. Percentage of aneuploid cancers correlated with the grade of tumours. Significant differences between tumours with 3 different locations were not found. Metastatic carcinoma cells in lymph nodes had significantly more cells in S-phase as compared to primary tumours.
Collapse
Affiliation(s)
- M Korabiowska
- UNIV GOTTINGEN,DEPT MAXILLOFACIAL SURG,D-37075 GOTTINGEN,GERMANY. UNIV GOTTINGEN,DEPT MED INFORMAT,D-37075 GOTTINGEN,GERMANY
| | | | | | | | | | | |
Collapse
|
23
|
|
24
|
|
25
|
|